<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933827</url>
  </required_header>
  <id_info>
    <org_study_id>CT31</org_study_id>
    <nct_id>NCT02933827</nct_id>
  </id_info>
  <brief_title>Adipose-derived Stem Cells (ADSCs) for Moderate to Severe Chronic Kidney Disease</brief_title>
  <official_title>A Phase I/II Study to Evaluate the Safety and Efficacy of Allogeneic Infusion of Adipose-Derived Stem Cells in Moderate to Severe Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UnicoCell Biomed CO. LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Protech Pharmaservices Corporation (PPC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UnicoCell Biomed CO. LTD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To assess the safety of allogeneic injection of expanded ADSCs to patients with Moderate&#xD;
           to Severe Chronic Kidney Disease&#xD;
&#xD;
        2. To assess the efficacy of allogeneic injection of expanded ADSCs to patients with&#xD;
           Moderate to Severe Chronic Kidney Disease&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Actual">April 23, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Week 48</time_frame>
    <description>for Phase I</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to Week 24 visit in estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>Week 0, 24</time_frame>
    <description>or Phase II</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in creatinine</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in blood urea nitrogen (BUN)</measure>
    <time_frame>Weeks 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in blood cystatin C</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in urine total protein-creatinine ratio (UPCR)</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in plasma neutrophil gelatinase-associated lipocalin (NGAL) by enzyme-linked immunosorbent assay (ELISA)</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in urine kidney injury molecule-1(KIM-1)</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in urine interleukin 18 (IL-18)</measure>
    <time_frame>Weeks 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in urine liver-type fatty acid-binding protein (L-FABP)</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in urine neutrophil gelatinase-associated lipocalin (NGAL)</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in urine cystatin C</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in hemoglobin A1c</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in fasting plasma glucose</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with hypoglycemia (defined as blood glucose &lt; 55 mg/dL or 3.0 mmol/L) at all post-treatment visits</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in body weight</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in urine microalbumin-to-creatinine ratio (UMCR)</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in eGFR</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Moderate to Severe Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Low dose:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ELIXCYTE 8 mL (ADSC 6.4*10^7 cells in total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ELIXCYTE 24 mL (ADSC 19.2*10^7 cells in total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ELIXCYTE 40 mL (ADSC 32.0*10^7 cells in total)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ELIXCYTE</intervention_name>
    <description>Adipose-derived stem cells (ADSCs)</description>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_label>Low dose:</arm_group_label>
    <arm_group_label>Middle dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A patient is eligible for the study if all of the followings apply:&#xD;
&#xD;
          1. Aged 20-80 years (inclusive)&#xD;
&#xD;
          2. With chronic kidney disease (CKD)stage 3B to 4 (eGFR 15 to 44 mL/min/1.73m2&#xD;
             (inclusive)) Note : eGFR = estimated glomerular filtration rate&#xD;
&#xD;
          3. Having provided informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any patient meeting any of the exclusion criteria will be excluded from study&#xD;
        participation.&#xD;
&#xD;
          1. Ascertained hypersensitivity to any component used in the study Note: including&#xD;
             gentamicin, DMSO, Agglutex (heperin)&#xD;
&#xD;
          2. With inadequate hematologic function with: absolute neutrophil count (ANC) &lt;1,500/μL&#xD;
             OR platelets &lt; 100,000/μL OR Hemoglobin &lt; 8 g/dL&#xD;
&#xD;
          3. With inadequate hepatic function with: serum bilirubin, aspartate aminotransferase&#xD;
             (AST), alanine aminotransferase (ALT) or alkaline phosphatase (AKP) &gt; 2.5 x the&#xD;
             institutional upper limit of normal (ULN)&#xD;
&#xD;
          4. With hemoglobin A1c (HbA1c) &gt; 8.0%&#xD;
&#xD;
          5. With serious prior or ongoing medical conditions (e.g. concomitant illness such as&#xD;
             cardiovascular (e.g. New York Heart Association grade III or IV), hepatic (e.g.&#xD;
             Child-Pugh Class C), psychiatric condition, alcoholism, drug abuse), medical history,&#xD;
             physical findings, ECG findings, or laboratory abnormality that in the investigators'&#xD;
             opinion could interfere with the results of the trial or adversely affect the safety&#xD;
             of the patient&#xD;
&#xD;
          6. Pregnant or lactating women or premenopausal with childbearing potential but not&#xD;
             taking reliable contraceptive method(s) during the study period&#xD;
&#xD;
          7. With body mass index (BMI) greater or equal to 36 kg/m2&#xD;
&#xD;
          8. With known history of human immunodeficiency virus (HIV) infection or any type of&#xD;
             hepatitis&#xD;
&#xD;
          9. Judged to be not applicable to this study by investigator such as difficulty of&#xD;
             follow-up observation&#xD;
&#xD;
         10. With any other serious diseases/medical history considered by the investigator not in&#xD;
             the condition to enter the trial&#xD;
&#xD;
         11. Having participated other investigational study within 4 weeks of entering this study&#xD;
&#xD;
         12. Known or suspected abuse of alcohol or narcotics&#xD;
&#xD;
         13. With known history of cancer within past 5 years&#xD;
&#xD;
         14. With any autoimmune disease&#xD;
&#xD;
         15. With cystic kidney disease or requiring kidney dialysis&#xD;
&#xD;
         16. With precancerous condition or with cancer within past 5 years before Screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mai-Szu Wu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Medical University Shuang Ho Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Chen</last_name>
    <phone>+886-2-2791-1826</phone>
    <phone_ext>158</phone_ext>
    <email>eva@unicocell.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taipei Medical University Shuang Ho Hospital</name>
      <address>
        <city>New Taipei City</city>
        <zip>235</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mai-Szu Wu, PhD</last_name>
      <email>maiszuwu@s.tmu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Mai-Szu Wu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital Linkou</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ya-Chung Tian, PhD</last_name>
      <phone>886-3-328-1200</phone>
      <phone_ext>8181</phone_ext>
      <email>dryctian@cgmh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Ya-Chung Tian, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

